Dark

ATRA
Atara Biotherapeutics, Inc
stock NASDAQ

Market Open

Nov 11, 2025 12:14:25 PM EST

12.52USD+1.914%(+0.24)30,351

0.00Bid 0.00Ask 0.00Spread

Pre-market

Nov 7, 2025 9:28:30 AM EST

11.08USD-6.844%(-0.81)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 27, 2022

07:58AM EST The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study Benzinga

Jan 26, 2022

04:55PM EST Fujifilm To Acquire Atara's Cell Therapy Manufacturing Facility For Total Upfront Financial Consideration Of $100M; Parties To Enter Long-Term Supply Agreement For Clinical And Commercial Product Manufacturing Benzinga

04:42PM EST Atara Biotherapeutics Enters Strategic Manufacturing Partnership With Fujifilm; Fujifilm To Acquire Co's Cell Therapy Manufacturing Facility For Total Upfront Financial Consideration Of $100M Benzinga

04:30PM EST Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm Business Wire

Jan 24, 2022

11:24AM EST Atara Biotherapeutics Highlights New Nature Study Titled 'Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM' Benzinga

11:24AM EST New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis Business Wire

Jan 14, 2022

11:13AM EST Shares of Atara Biotherapeutics, Inc. (ATRA) are gaining over 5% on Friday morning despite not stock-related news to drive the shares. RTTNews

Jan 10, 2022

08:30AM EST Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 7, 2022

04:01PM EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Jan 6, 2022

10:02AM EST Be The Match BioTherapies, Atara Biotherapeutics Announce Multi-Year Partnership Extension Benzinga

Jan 5, 2022

04:01PM EST Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 3, 2022

11:17AM EST JP Morgan Maintains Overweight on Atara Biotherapeutics, Raises Price Target to $27 Benzinga

Dec 14, 2021

09:03AM EST Shares of Atara Biotherapeutics, Inc. (ATRA), are trading 3 percent higher in pre-market on Tuesday after the company engaged in T-cell immunotherapy, announced efficacy and safety results from its study investigating tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. RTTNews

08:22AM EST The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks Benzinga

Dec 13, 2021

08:15PM EST Atara Biotherapeutics Announces Positive Results From Pivotal Phase 3 Trial Of Tab-cel RTTNews

07:15PM EST Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel(r) at the 63rd American Society of Hematology (ASH) Annual Meeting Business Wire

Dec 9, 2021

09:46PM EST Atara Biotherapeutics Announces Preliminary Results For ATA2271, A Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy For Solid Tumors, At ESMO Immuno-Oncology Congress 2021 Benzinga

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

08:08AM EST Atara : Vitro Functional Studies Show Potent Antitumor Activity Of ATA2271 Following Repeat Antigen Stimulation RTTNews

08:00AM EST Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021 Business Wire

Dec 3, 2021

04:01PM EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Nov 30, 2021

04:48PM EST Atara Announces European Medicines Agency Validates Atara Biotherapeutics' Marketing Authorization Application For Tabelecleucel For Treatment Of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Benzinga

08:45AM EST EMA Validates Atara' MAA For Tabelecleucel For Treatment Of EBV+ PTLD RTTNews

08:30AM EST European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Business Wire

Nov 8, 2021

04:01PM EST Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences Business Wire

Nov 5, 2021

04:01PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

12:08PM EDT How Bad Are Atara Biotherapeutics's Earnings? | Return On Capital Employed Benzinga

Nov 4, 2021

09:30AM EDT Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel(r) Pivotal Phase 3 (ALLELE) Data Business Wire

08:20AM EDT Atara Biotherapeutics Q3 EPS $(0.90) Beats $(0.94) Estimate, Sales $5.37M Beat $3.92M Estimate Benzinga

07:31AM EDT Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress Business Wire

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 28, 2021

04:02PM EDT Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021 Business Wire

Oct 13, 2021

01:38PM EDT Atara Biotherapeutics Highlights Presentation Of New Magnetization Transfer Ratio Imaging Data And Two-Year Clinical Data From Open Label Extension Of ATA188 For Progressive Multiple Sclerosis At ECTRIMS 2021 Benzinga

01:38PM EDT The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal Benzinga

07:35AM EDT Atara Presents Two-Year Data From Open Label Extension Of ATA188 For Progressive Multiple Sclerosis RTTNews

07:30AM EDT Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021 Business Wire

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 4, 2021

07:39AM EDT Atara Biotherapeutics And Pierre Fabre Enter Strategic Collaboration To Commercialize Tabelecleucel; Atara To Receive Upfront Payment Of $45M, And Up To ~$320M In Total Milestones Benzinga

07:37AM EDT Atara Biotherapeutics And Pierre Fabre Enter Strategic Collaboration To Commercialize Tabelecleucel RTTNews

07:30AM EDT Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel(r)) Business Wire

Oct 1, 2021

06:14PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

Sep 29, 2021

03:46AM EDT Atara Biotherapeutics To Present Phase 1 Study Update Of ATA188 In Progressive Multiple Sclerosis At ECTRIMS 2021 RTTNews

Sep 27, 2021

09:13AM EDT Atara Biotherapeutics, Inc. (ATRA) said the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted accelerated assessment to the company's lead product candidate, tabelecleucel, for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. RTTNews

08:38AM EDT EMA Grants Atara Accelerated Assessment Of Tab-cel For The Treatment Of Epstein-Barr Virus Positive RTTNews

08:35AM EDT Atar Biotherapeutics Reports European Medicines Agency Grant For Co.'s Accelerated Assessment Of tab-cel For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease Benzinga

08:30AM EDT European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel(r) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD) Business Wire

Sep 3, 2021

04:01PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

Sep 2, 2021

08:30AM EDT Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference Business Wire

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 9, 2021

04:38PM EDT Atara Biotherapeutics Q2 EPS $(0.91) Misses $(0.89) Estimate, Sales $3.87M Beat $3.84M Estimate Benzinga

04:02PM EDT Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Business Wire

04:01PM EDT Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors Business Wire

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 2, 2021

06:00PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

08:30AM EDT Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021 Business Wire

Jul 2, 2021

04:13PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) RTTNews

Jul 1, 2021

04:30PM EDT Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers Business Wire

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

Jun 7, 2021

12:40PM EDT Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients Benzinga

10:31AM EDT Atara Biotherapeutics Highlights Presentation Of Tab-cel Long-Term Overall Survival Data For Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant: All Patients Showed Complete Or Partial Response At 1 Year Benzinga

10:30AM EDT Atara Biotherapeutics Presents Positive Tab-cel(r) Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect Business Wire

Jun 4, 2021

04:01PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

May 13, 2021

04:01PM EDT Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit Business Wire

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2021 Benzinga

07:14AM EDT JP Morgan Upgrades Atara Biotherapeutics to Overweight, Raises Price Target to $29 Benzinga

May 10, 2021

08:30AM EDT Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer Business Wire

May 7, 2021

04:01PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

May 5, 2021

07:03AM EDT HC Wainwright & Co. Maintains Buy on Atara Biotherapeutics, Lowers Price Target to $31 Benzinga

May 4, 2021

04:09PM EDT Atara Biotherapeutics Q1 EPS $(0.86) Beats $(0.92) Estimate, Sales $3.55M Beat $1.60M Estimate Benzinga

04:01PM EDT Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Business Wire

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 27, 2021

05:51PM EDT Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Business Wire

Apr 2, 2021

04:35PM EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

Mar 14, 2021

04:00PM EDT Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel(r) Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Business Wire

Mar 9, 2021

04:01PM EST Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference Business Wire

Mar 5, 2021

04:01PM EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire

Mar 2, 2021

11:00AM EST Atara Biotherapeutics Shares Spike Higher; Hearing Citi Upgrades To Buy Benzinga

07:25AM EST Antares Pharma Reaffirms FY21 Sales Guidance of $175M-$200M Benzinga

Mar 1, 2021

04:11PM EST Atara Biotherapeutics Q4 EPS $(0.95) Misses $(0.74) Estimate Benzinga

04:05PM EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress Business Wire

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 18, 2021

04:01PM EST Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 Business Wire

Feb 8, 2021

09:04AM EST Atara Biotherapeutics Highlights Presentation Of Key Data For Advancing Development Of Tab-cel, ATA188 At 2021 Transplantation & Cellular Therapy Meeting Digital Experience Benzinga

09:00AM EST Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel(r) and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Business Wire

Jan 19, 2021

04:15PM EST Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Business Wire

Jan 10, 2021

04:06PM EST Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 6, 2021

08:30AM EST Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 4, 2021

08:47AM EST Atara Provides Regulatory Update For Tab-Cel For Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease RTTNews

07:38AM EST Atara Says Has Not Yet Initiated The Biologics License Application For Tab-Cel; Remains On Track To Complete Filing In Q3, Says 'awaiting a procedural decision from the FDA related to how the historical non-pivotal data should be presented' Benzinga

07:30AM EST Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(r) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Business Wire

Dec 26, 2020

09:16AM EST The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks Benzinga

Dec 8, 2020

09:43PM EST Atara Biotherapeutics Prices Underwritten Public Offering Of 5.10 Mln Shares At $24.50/shr RTTNews

09:26PM EST Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering Business Wire

08:15AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

06:21AM EST HC Wainwright & Co. Maintains Buy on Atara Biotherapeutics, Raises Price Target to $31 Benzinga

Dec 7, 2020

04:08PM EST Atara Biotherapeutics Reports $150M Common Stock Offering Benzinga

04:07PM EST Atara Biotherapeutics Announces Proposed Offering of Common Stock Business Wire

07:22AM EST Atara Biotherapeutics Presents First Preclinical Evaluation Of ATA3219 At ASH RTTNews

07:06AM EST Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting Benzinga

06:59AM EST Bayer, Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors; Atara to Receive Upfront Payment of $60M Plus Milestones Up to $610M Benzinga

Dec 6, 2020

11:43PM EST Bayer (BAYZF.PK, BAYRY.PK, BYR.L) and Atara Biotherapeutics, Inc. (ATRA) announced worldwide license deal and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. RTTNews

11:00PM EST Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors Business Wire

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 18, 2020

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

Nov 17, 2020

09:52AM EST Stocks Trading Near 52-Week Highs Just After Open On Tuesday, Nov. 17, 2020: CAPA, FSRVU, TRTN, ATRA, BEEMW, COOP, NBACU, STKL, KLAC, DLB, PCGU, GNTX, CSV, CCCC, DAC, BHVN, DTP, ACHC, GM, QCOM, FOLD, SNX, GRWG, CHI, CHY, UPWK Benzinga

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 16, 2020

04:01PM EST Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences Business Wire

Nov 15, 2020

10:06AM EST Atara Biotherapeutics To Present 15-Month Safety And Efficacy Data In Phase1a Study Of ATA188 At ECF RTTNews

10:00AM EST Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting Business Wire

Nov 12, 2020

08:37AM EST Atara Presents Data On ATA3271, Next-Generation Allogeneic Mesothelin-Targeted CAR T To Treat Solid Tumors RTTNews

08:34AM EST Atara Biotherapeutics Presents New Preclinical Data On ATA3271 Next-Generation Allogeneic Mesothelin-Targeted CAR T To Treat Solid Tumors At 35th Society For Immunotherapy Of Cancer Annual Meeting Benzinga

08:30AM EST Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020) Business Wire

Nov 9, 2020

04:03PM EST Atara Biotherapeutics Announces Interim Analysis Of The Pivotal 302 Study Showed Tab-cel In EBV+ PTLD Achieved A 50% Objective Response Rate And Safety Consistent With Historical Data Benzinga

04:02PM EST Atara Biotherapeutics Q3 EPS $(0.92) Beats $(1.09) Estimate Benzinga

04:01PM EST Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress Business Wire

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

04:01PM EST Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020 Business Wire

Sep 15, 2020

09:41AM EDT Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $78 Benzinga

Sep 14, 2020

08:42AM EDT Atara Biotherapeutics To Present Clinical Data In Epstein-Barr Virus-Driven Acquired & Primary Immunodeficiency Lymphoproliferative Diseases From Tab-Cel Expanded Access Program In E-Poster At ESMO 2020 Virtual Congress Benzinga

08:30AM EDT Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel(r) Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress Business Wire

Sep 11, 2020

08:08AM EDT Atara Announces All Progressive Multiple Sclerosis Patients with Disability Improvement At Six Months RTTNews

08:01AM EDT Atara Biotherapeutics Reports All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188 Benzinga

08:00AM EDT Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188 Business Wire

Sep 10, 2020

12:25PM EDT Why Atara Biotherapeutics Is Trading Higher Today Benzinga

Sep 8, 2020

07:06AM EDT Atara Biotherapeutics Announces FDA Clearance Of IND For ATA2271 For The Treatment Of Advanced Mesothelioma RTTNews

07:02AM EDT Atara Biotherapeutics Announces FDA Clearance Of IND For ATA2271 Benzinga

07:00AM EDT Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors Business Wire

Sep 1, 2020

07:14AM EDT Atara Biotherapeutics To Present 12-Month Data From Four Cohorts In Phase 1a Study Of ATA188 At MSVirtual2020 RTTNews

07:00AM EDT Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020 Business Wire

Aug 6, 2020

09:48AM EDT Stifel Maintains Buy on Atara Biotherapeutics, Lowers Price Target to $28 Benzinga

06:39AM EDT HC Wainwright & Co. Maintains Buy on Atara Biotherapeutics, Raises Price Target to $26 Benzinga

Aug 5, 2020

04:15PM EDT Atara Biotherapeutics Q2 EPS $(1.14) Beats $(1.18) Estimate Benzinga

04:01PM EDT Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress Business Wire

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 29, 2020

04:01PM EDT Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 Business Wire